NCT04673383View on ClinicalTrials.gov

SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

October 1, 2022

Study Completion Date

December 22, 2022

Conditions
Major Depressive Disorder
Interventions
DRUG

SPL026

Intravenous solution

DRUG

Placebo

SPL026-matched placebo

Trial Locations (2)

L34 1BH

MAC Clinical Research, Liverpool

Unknown

Hammersmith Medicines Research, London

All Listed Sponsors
lead

Small Pharma Ltd

INDUSTRY

NCT04673383 - SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients | Biotech Hunter | Biotech Hunter